Researchers and families unite to address Huntington's disease, exploring innovative therapies and fostering connections at ...
Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class therapies ...
Entry to the event, that will be held at the Shakuntala Jagannath Shetty Auditorium on November 1 from 6pm to 8pm, is free.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback